Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Classement en actions #6138
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Prix de l'action
$154.04
Capitalisation boursière
$2.21B
Changement (1 jour)
-0.19%
Changement (1 an)
172.88%
Pays
US
Échange Palvella Therapeutics, Inc. (PVLA)

Catégorie

Ratio P/B pour Palvella Therapeutics, Inc. (PVLA)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Palvella Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Palvella Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH